A randomized and comparative study of ipragliflozin and sitagliptin in patients with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Ipragliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Results (n=66) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.